远程医疗诊所中阿片类药物和烟草使用障碍的联合治疗：突破障碍的病例报告
Concurrent Treatment of Opioid and Tobacco Use Disorder in a Telemedicine Clinic: Case Report of Breaking Through Barriers.
作者信息
Michero Darcy, Monico Laura, Pielsticker Peyton, Mooney Larissa J, Glasner Suzette
机构信息
Department of Clinical Affairs, Digital Therapeutics, New York, NY, United States.
Department of Psychiatry, University of California, Los Angeles, CA, United States.
出版信息
JMIR Form Res. 2025 May 15;9:e72872. doi: 10.2196/72872.
Abstract
RR2-10.1177/20552076241258400.
摘要
RR2 - 10.1177/20552076241258400. （此内容似乎是一个特定编号或代码，难以直接按常规方式翻译出完整语义，保留原文形式供你参考其在原始语境中的作用。）
相似文献
1
Concurrent Treatment of Opioid and Tobacco Use Disorder in a Telemedicine Clinic: Case Report of Breaking Through Barriers.
JMIR Form Res. 2025 May 15;9:e72872. doi: 10.2196/72872.
2
Health Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study.
JMIR Form Res. 2025 Jun 19;9:e66596. doi: 10.2196/66596.
3
Telemedicine to improve access to medications for opioid use disorder in Illinois, 2022-2024.
Int J Drug Policy. 2025 Mar;137:104729. doi: 10.1016/j.drugpo.2025.104729. Epub 2025 Feb 6.
4
Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.
J Subst Abuse Treat. 2015 May;52:40-7. doi: 10.1016/j.jsat.2014.12.002. Epub 2014 Dec 22.
5
Facilitators and Challenges to Adoption of a Digital Health Tool for Opioid Use Disorder Treatment in Primary Care: Mixed Methods Study.
J Med Internet Res. 2025 Jul 10;27:e69953. doi: 10.2196/69953.
6
The Support Hospital Opioid Use Disorder Treatment (SHOUT) Texas program implementation strategy for expanding treatment for hospitalized adults with opioid use disorder.
J Subst Use Addict Treat. 2025 Jan;168:209539. doi: 10.1016/j.josat.2024.209539. Epub 2024 Oct 11.
7
Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.
Drug Alcohol Depend. 2025 Jan 1;266:112522. doi: 10.1016/j.drugalcdep.2024.112522. Epub 2024 Dec 4.
8
Mindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment: A Randomized Clinical Trial.
JAMA Netw Open. 2025 Jan 2;8(1):e2454950. doi: 10.1001/jamanetworkopen.2024.54950.
9
Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series.
J Addict Dis. 2024 Oct-Dec;42(4):572-577. doi: 10.1080/10550887.2023.2273191. Epub 2023 Nov 1.
10
mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder.
Addict Sci Clin Pract. 2025 Jan 29;20(1):6. doi: 10.1186/s13722-025-00538-1.
本文引用的文献
1
Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder.
Subst Abuse Treat Prev Policy. 2025 Feb 18;20(1):8. doi: 10.1186/s13011-024-00631-9.
2
Feasibility and acceptability of a novel digital therapeutic combining behavioral and pharmacological treatment for opioid use disorder.
Digit Health. 2024 May 29;10:20552076241258400. doi: 10.1177/20552076241258400. eCollection 2024 Jan-Dec.
3
Buprenorphine Dispensing after Elimination of the Waiver Requirement.
N Engl J Med. 2024 Apr 25;390(16):1530-1532. doi: 10.1056/NEJMc2312906.
4
Primary care professionals' perspectives on tailoring buprenorphine training for rural practice.
J Rural Health. 2024 Sep;40(4):671-680. doi: 10.1111/jrh.12832. Epub 2024 Mar 14.
5
Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
Harm Reduct J. 2023 Dec 21;20(1):180. doi: 10.1186/s12954-023-00918-3.
6
Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines.
JAMA Health Forum. 2023 Jul 7;4(7):e231982. doi: 10.1001/jamahealthforum.2023.1982.
7
Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
JAMA Netw Open. 2023 Jan 3;6(1):e2252381. doi: 10.1001/jamanetworkopen.2022.52381.
8
Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
J Nurs Scholarsh. 2023 May;55(3):655-664. doi: 10.1111/jnu.12871. Epub 2023 Jan 9.
9
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.
10
Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19.
J Gen Intern Med. 2022 Apr;37(5):1331-1333. doi: 10.1007/s11606-021-07249-8. Epub 2022 Jan 3.
Zotero 插件